JPH03264532A - Remedy containing activated vitamin d - Google Patents
Remedy containing activated vitamin dInfo
- Publication number
- JPH03264532A JPH03264532A JP6280590A JP6280590A JPH03264532A JP H03264532 A JPH03264532 A JP H03264532A JP 6280590 A JP6280590 A JP 6280590A JP 6280590 A JP6280590 A JP 6280590A JP H03264532 A JPH03264532 A JP H03264532A
- Authority
- JP
- Japan
- Prior art keywords
- dihydroxyvitamin
- 1alpha
- hydroxyvitamin
- alveolar bone
- activated vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940046008 vitamin d Drugs 0.000 title claims abstract description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 9
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims abstract description 9
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 8
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 8
- 239000011710 vitamin D Substances 0.000 claims abstract description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 8
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims abstract description 3
- WMYIVSWWSRCZFA-RWVJFQLJSA-N 1,25-Dihydroxyvitamin D3-26,23-lactone Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)[C@H]1C[C@@](C)(O)C(=O)O1 WMYIVSWWSRCZFA-RWVJFQLJSA-N 0.000 claims abstract 2
- 208000002679 Alveolar Bone Loss Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 4
- 206010003694 Atrophy Diseases 0.000 abstract description 2
- 230000037444 atrophy Effects 0.000 abstract description 2
- FCKJYANJHNLEEP-OIMXRAFZSA-N 24,25-Dihydroxyvitamin D Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@H](O)CCC1=C FCKJYANJHNLEEP-OIMXRAFZSA-N 0.000 abstract 1
- IJNDMZIDDKVXHR-MYEQSZOMSA-N 25-Hydroxyvitamin D3-26,23-lactone Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C/1C(CC[C@@H](O)C\1)=C)C)[C@@H]1C[C@@](C)(O)C(=O)O1 IJNDMZIDDKVXHR-MYEQSZOMSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004283 incisor Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 4
- 206010068975 Bone atrophy Diseases 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Abstract
Description
【発明の詳細な説明】 〈産業上の利用分野〉 本発明は歯槽骨萎縮症の治療剤に関するものである。[Detailed description of the invention] <Industrial application field> The present invention relates to a therapeutic agent for alveolar bone atrophy.
〈従来の技術〉
歯周疾患（俗称、歯槽Ｉ漏〉におかされると、歯槽骨骨
頂部より骨吸収が始まる。骨吸収の進行に従って骨萎縮
が進行すると、歯それ自体は全く無傷であっても、その
歯を支える歯槽骨を初めとする南側組織が破壊されるこ
ととなる。その結果、歯の動揺が激しくなり、遂には抜
崗の止むなきに到ることがほとんどである。そのため、
歯槽骨萎縮症を防止乃至改善する治療剤が望まれている
。<Prior art> When periodontal disease (commonly known as alveolar I leakage) occurs, bone resorption begins from the top of the alveolar bone.As bone atrophy progresses as bone resorption progresses, the tooth itself remains completely intact. However, the southern tissue, including the alveolar bone that supports the tooth, is destroyed.As a result, the tooth becomes more mobile, and in most cases, extraction is unavoidable. ,
A therapeutic agent that prevents or improves alveolar bone atrophy is desired.
しかしながら、かかる歯周疾患患者の歯槽骨萎縮症の治
療剤については、従来、全く知られていない。However, no therapeutic agent for alveolar bone atrophy in periodontal disease patients has been known so far.
方、活性型ビタミンＤの１つである１α−ヒドロキシビ
タミンＤが骨粗鬆症、慢性腎不全の骨病変、副甲状腺機
能低下症、骨軟化症に対して有効であることは判明して
いるが、歯槽骨萎縮症に対して、どの様な効果を示すか
については、全く知られていない。On the other hand, 1α-hydroxyvitamin D, one of the active forms of vitamin D, has been shown to be effective against osteoporosis, bone lesions of chronic renal failure, hypoparathyroidism, and osteomalacia. It is completely unknown what kind of effect it has on bone atrophy.
〈発明が解決しようとする問題点〉
そこで、本発明者らは、先ず整形外科領域等において、
骨萎縮度の判定法として広く用いられているＭＤ法を歯
槽骨の萎縮度の評価に応用した歯槽骨の骨萎縮度評価法
を考案した（公開特許公報昭６２−２６６０５３．公開
昭和６２年１１月１８日）。<Problems to be solved by the invention> Therefore, the present inventors first solved the problem in the field of orthopedics, etc.
We devised a method for evaluating the degree of alveolar bone atrophy by applying the MD method, which is widely used as a method for determining the degree of bone atrophy, to the evaluation of the degree of atrophy of the alveolar bone (Publication Patent Publication No. 1982-266053. Published in November 1988). 18th of the month).
更に、本発明者らは、かかる歯槽骨の骨萎縮度評価法を
用いて、歯槽骨萎縮症の治療剤につき鋭意研究した結果
、活性型ビタミンＤが、歯槽骨萎縮症の治療に有効であ
ることを見出し、本発明に到達した。Furthermore, the present inventors have conducted extensive research into therapeutic agents for alveolar bone atrophy using such a method for evaluating the degree of alveolar bone atrophy, and have found that active vitamin D is effective in treating alveolar bone atrophy. They discovered this and arrived at the present invention.
〈問題点を解決するための手段〉
即ち、本発明は、活性型ビタミンＤを有効成分とする歯
槽骨萎縮症の治療剤である。<Means for Solving the Problems> That is, the present invention is a therapeutic agent for alveolar bone atrophy containing active vitamin D as an active ingredient.
本発明における活性型ビタミンＤとは活性型ビタミンＤ
２．活性型ビタミンＤ３およびそれらの誘導体を含むも
のであり、その具体例としては、例えば１α−ヒドロキ
シビタミンＤ、１α、２４ジヒドロキシビタミンＤ、１
α、２５−ジヒドロキシビタミンＤ、１α、 ２４．２
５−１−ジヒドロキシビタミンＤ、 ２４．２４−ジフ
ルオロ−１α、２５−ジヒドロキシビタミンＤ、 ２６
．２６．２６．２７．２７．２７へキサフルオロ−１α
、２５−ジヒドロキシビタミンＤ、２５−ヒドロキシビ
タミンＤ３−２６．２３−ラクトン、１α、２５−ジヒ
ドロキシビタミンＤ３２６、２３−ラクトンが挙げられ
る。なかでも、１αヒドロキシビタミンＤ３．１α、２
４（Ｒ）−ジヒドロキシビタミンＤ３．１α、２５−ジ
ヒドロキシビタミンＤ３が好ましい。Active vitamin D in the present invention refers to active vitamin D
2. Contains active vitamin D3 and derivatives thereof, such as 1α-hydroxyvitamin D, 1α,24 dihydroxyvitamin D, 1α-hydroxyvitamin D, 1α-hydroxyvitamin D, 1α-hydroxyvitamin D,
α, 25-dihydroxyvitamin D, 1α, 24.2
5-1-dihydroxyvitamin D, 24.24-difluoro-1α, 25-dihydroxyvitamin D, 26
．． 26.26.27.27.27 Hexafluoro-1α
, 25-dihydroxyvitamin D, 25-hydroxyvitamin D3-26.23-lactone, 1α,25-dihydroxyvitamin D326, 23-lactone. Among them, 1α hydroxyvitamin D3.1α, 2
4(R)-dihydroxyvitamin D3.1α, 25-dihydroxyvitamin D3 is preferred.
これらの有効成分は公知の方法で適当な賦形剤等を用い
て、軟カプセル剤、硬カブヒル剤２錠剤。These active ingredients are prepared by a known method using appropriate excipients, etc., into soft capsules and two hard tablets.
シロップ剤等の経口剤、注射剤、または外用剤として使
用できる。It can be used as an oral preparation such as a syrup, an injection, or an external preparation.
かかる賦形剤としては植物油（例えばトウモロコシ油、
綿実油、ココナツツ油、アーモンド油。Such excipients include vegetable oils (e.g. corn oil,
Cottonseed oil, coconut oil, almond oil.
落花生油等）、中鎖脂肪酸グリセライド等の油状エステ
ル、鉱物油、ワセリン、ｌＩ物油脂、セルロース誘導体
く結晶セルロース、ヒドロキシプロピルセルロース、ヒ
ドロキシプロピルメチルセルロース、メチルセルロース
）、ポリビニルピロリド３−
ン、デキストリン、乳糖、マンニトール、ソルビトール
、デンプン等が挙げられる。(peanut oil, etc.), oily esters such as medium-chain fatty acid glycerides, mineral oil, vaseline, lI fats and oils, cellulose derivatives (crystalline cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose), polyvinylpyrrolidone, dextrin, lactose , mannitol, sorbitol, starch, etc.
有効成分の投与嬢は、通常０．０１〜１０αｇ／日／人
程度で、好ましくは０．２５〜４．０αｇ／日／人であ
り、投与回数は通常１〜３回／日であり、このような条
件を満足するように製剤を調製するのが好ましい。The dose of the active ingredient is usually about 0.01-10αg/day/person, preferably 0.25-4.0αg/day/person, and the number of administrations is usually 1-3 times/day. It is preferable to prepare a formulation so as to satisfy these conditions.
本発明の方法は既存の薬物療法治療剤と併用することも
可能である。The methods of the invention can also be used in combination with existing pharmacotherapeutic treatments.
次に、実施例を用いて、本発明を詳述する。Next, the present invention will be explained in detail using examples.
［実施例］
２症例の歯周疾患患者（症例Ａ及び症例Ｂ〉について、
公開特許公報昭６２〜２６６０５３の方法で、１段の高
さ５ ｍｍで５段のアルミニウム階段（最低５胴、最高
２５ｍ）と共に、下顎左側第２切歯から右側第２切歯ま
での４本の切歯のＸ線像を撮影し、ミクロデンシトメー
ターを用いて中切歯の根尖部から １／３の部位の陰影
濃度を測定してチャートに５倍に拡大して記録し、アル
ミニウム階段の陰影′ａ度も測定して記録した。チャー
トより、１−２ Ｌ＋：左側第２切歯と左側第１切歯と
の間
Ｌ＋ −Ｒ＋ ：左側第１切歯と右側第１切歯との間
Ｒ＋ −Ｒ２：右側第１切歯と右側第２切南との間
について、公開特許公報昭６２−２６６０５３と同様に
して、歯槽骨幅ｄ、アルミニウム階段の段数に換算した
吸収面積ΣＧＳ並びに最大吸収度Ｇ５ｌｌ１ａｘを測定
した。この測定値を投与前値とした。[Example] Regarding two cases of periodontal disease patients (case A and case B),
Using the method described in Japanese Patent Publication No. 1982-266053, we constructed 4 aluminum stairs from the left second incisor of the mandible to the right second incisor, along with 5 aluminum steps (minimum 5 trunks, maximum 25 m) with each step height 5 mm. An X-ray image of the central incisor was taken, and the density of the shading in the 1/3 region from the root apex of the central incisor was measured using a microdensitometer and recorded on a chart with 5x magnification. The degree of shading of the stairs was also measured and recorded. From the chart, 1-2 L+: Between the second incisor on the left side and the first incisor on the left side L+ -R+: Between the first incisor on the left side and the first incisor on the right side R+ -R2: Between the first incisor on the right side The alveolar bone width d, the absorption area ΣGS converted to the number of steps of an aluminum staircase, and the maximum absorption degree G5ll1ax were measured between the right side and the second cut south in the same manner as in the published patent publication No. 62-266053. This measured value was taken as the pre-administration value.
１α−ヒドロキシビタミンＤ３１．０αｇ／日の投与を
開始し、２〜５か月毎に、前記と同様にして、ｄ、ΣＧ
Ｓ、ＧＳｍａｘを測定し、投与前値力）らの変化率［（
投与接値−投与前値）／投与前値ｘ １００］が、±１
０％以内を評点Ｑ、１０％以上の増加を評点−１，１０
％以上の減少を評点＋１と設定し、ｄ、ΣＧＳ、ＧＳｍ
ａｘの評点の合計が３〜２を改善、１〜−１を不変、−
２〜−３を悪化と判定した。Administration of 31.0αg/day of 1α-hydroxyvitamin D was started, and d, ΣG
S, GSmax was measured, and the rate of change of the pre-administration value force) [(
administration value - pre-administration value)/pre-administration value x 100] is ±1
An increase of 0% or less is a rating of Q, an increase of 10% or more is a rating of -1, 10.
A decrease of % or more is set as a score +1, and d, ΣGS, GSm
Total ax score improved from 3 to 2, unchanged from 1 to -1, -
2 to -3 was determined to be worse.
測定結果、評点並びに効果判□定結果を部位別に第１表
（症例へ）並びに第２表（症例Ｂ）に示す。The measurement results, ratings, and efficacy evaluation results are shown by site in Table 1 (for cases) and Table 2 (for case B).
症例Ａでは、各部位とも、投与後５〜８か月後から改善
効果が認められ、以後、改善効果が持続している。症例
Ｂでは、各部位とも投与後５か月後から改善効果が認め
られ、以後も、はぼ改善効果が維持されている。In case A, the improvement effect was observed in each site 5 to 8 months after administration, and the improvement effect continued thereafter. In case B, the improvement effect was observed in each site 5 months after administration, and the improvement effect on the skin was maintained even after that.
第２表（症例Ｂ） ９ 第１表〈症例Ａ〉Table 2 (Case B) 9 Table 1〈Case A〉
Claims (2)
の治療剤。(1) A therapeutic agent for alveolar bone atrophy containing active vitamin D as an active ingredient.
、１α，２４−ジヒドロキシビタミンＤ、１α，２５−
ジヒドロキシビタミンＤ、１α，２４，２５−トリヒド
ロキシビタミンＤ、２４，２４−ジフルオロ−１α、２
５−ジヒドロキシビタミンＤ、２６，２６，２６，２７
，２７，２７−ヘキサフルオロ−１α、２５−ジヒドロ
キシビタミンＤ、２５−ヒドロキシビタミンＤ＿３−２
６，２３−ラクトン、１α，２５−ジヒドロキシビタミ
ンＤ＿３−２６，２３−ラクトンからなる群から選ばれ
たものである請求項１記載の歯槽骨萎縮症の治療剤。(2) Active vitamin D is 1α-hydroxyvitamin D
, 1α,24-dihydroxyvitamin D, 1α,25-
Dihydroxyvitamin D, 1α,24,25-trihydroxyvitamin D, 24,24-difluoro-1α,2
5-dihydroxyvitamin D, 26,26,26,27
, 27,27-hexafluoro-1α, 25-dihydroxyvitamin D, 25-hydroxyvitamin D_3-2
The therapeutic agent for alveolar bone atrophy according to claim 1, which is selected from the group consisting of 6,23-lactone and 1α,25-dihydroxyvitamin D_3-26,23-lactone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6280590A JPH03264532A (en) | 1990-03-15 | 1990-03-15 | Remedy containing activated vitamin d |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6280590A JPH03264532A (en) | 1990-03-15 | 1990-03-15 | Remedy containing activated vitamin d |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH03264532A true JPH03264532A (en) | 1991-11-25 |
Family
ID=13210919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6280590A Pending JPH03264532A (en) | 1990-03-15 | 1990-03-15 | Remedy containing activated vitamin d |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03264532A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1208843A4 (en) * | 1999-08-31 | 2002-09-11 | Chugai Pharmaceutical Co Ltd | Soft capsules |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60185715A (en) * | 1984-03-05 | 1985-09-21 | Teijin Ltd | Bone formation accelerator |
| JPS61109722A (en) * | 1984-11-01 | 1986-05-28 | Kureha Chem Ind Co Ltd | Antidiabetic drug for bone reducing disease |
| JPS63166829A (en) * | 1986-12-29 | 1988-07-11 | Kureha Chem Ind Co Ltd | Agent for increasing bone strength |
| JPS6483019A (en) * | 1987-09-25 | 1989-03-28 | Sunstar Inc | Composition used in oral cavity for orthodontic therapy of tooth |
-
1990
- 1990-03-15 JP JP6280590A patent/JPH03264532A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60185715A (en) * | 1984-03-05 | 1985-09-21 | Teijin Ltd | Bone formation accelerator |
| JPS61109722A (en) * | 1984-11-01 | 1986-05-28 | Kureha Chem Ind Co Ltd | Antidiabetic drug for bone reducing disease |
| JPS63166829A (en) * | 1986-12-29 | 1988-07-11 | Kureha Chem Ind Co Ltd | Agent for increasing bone strength |
| JPS6483019A (en) * | 1987-09-25 | 1989-03-28 | Sunstar Inc | Composition used in oral cavity for orthodontic therapy of tooth |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1208843A4 (en) * | 1999-08-31 | 2002-09-11 | Chugai Pharmaceutical Co Ltd | Soft capsules |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Novaes Jr et al. | Immediate implants placed into infected sites: a clinical report. | |
| Bernal et al. | Clinical management of mobile teeth | |
| US7115252B2 (en) | Therapeutic compositions and methods of use thereof | |
| Malevez et al. | Marginal bone levels at Brånemark system implants used for single tooth restoration. The influence of implant design and anatomical region | |
| Ivey et al. | Orthodontic extrusion: Its use in restorative dentistry | |
| US11612581B2 (en) | Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects | |
| Heasman et al. | The use of topical flurbiprofen as an adjunct to non‐surgical management of periodontal disease | |
| RU2107512C1 (en) | Pharmaceutical composition for osteoinduction and method for generation of a new bone | |
| Nasjleti et al. | Replantation of mature teeth without endodontics in monkeys | |
| FR2618670A1 (en) | Medicinal preparation based on essential oils, as well as toothpaste and chewing gum containing it | |
| Calvert | Maxillary central incisor with type V canal morphology: case report and literature review | |
| Robinson | Aneurysmal bone cyst: a hybrid lesion? | |
| Prato et al. | Periodontal regenerative therapy with coverage of previously restored root surfaces | |
| Hirsch et al. | Root coverage and pocket reduction as combined surgical procedures | |
| JPH03264532A (en) | Remedy containing activated vitamin d | |
| Jung et al. | Anterior maxillary defect reconstruction with a staged bilateral rotated palatal graft | |
| Soxman et al. | Noninvasive and minimally invasive treatment of dental caries | |
| Gold | Root canal calcification associated with prednisone therapy: a case report | |
| Gerner et al. | External root resorption in patients with secondary bone‐grafting of alveolar clefts | |
| Misilli et al. | Evaluation of marginal microleakage in composite restorations with different placement techniques | |
| RADU et al. | GLASS-IONOMER AND RESIN COMPOSITE RESTORATIONS IN PRIMARY MOLARS: A 36-MONTH PROSPECTIVE CLINICAL STUDY. | |
| CA2219354A1 (en) | Prevention of tooth loss by the administration of alendronate or its salts | |
| Lang et al. | Comparison of implant and provisional placement protocols in sinus-augmented bone: a preliminary report. | |
| US20070020200A1 (en) | Therapeutic compositions and methods of use thereof | |
| Rabie et al. | Treatment of a maxillary canine with external inflammatory root resorption |